Celgene owns 14.5% of Epizyme ahead of the initial public offering

Epizyme, a US-based biotech company backed by peer Celgene’s corporate venturing unit, plans to raise $69m in its flotation on the Nasdaq stock exchange.

Celgene owns 14.5% of Epizyme ahead of the initial public offering (IPO), after investing the portfolio company’s series C round, while venture capital firms New Enterprise Associates owns 25.1%, Kleiner Perkins Caufield & Byers 20.1%, Bay City Capital 15.5% and MPM Capital 12.8%.

In April 2012, Epizyme sold Celgene an exclusive license to its DOT1L programme…